PHILADELPHIA, February 4, 2011 /PRNewswire/ -- AVAX
Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or the "Company")
today announced that it filed a Form 10 with the Securities and
Exchange Commission ("SEC"). Upon the effectiveness of this Form
10, AVAX will once again become a publicly reporting company. The
Company intends to seek to have its common stock trade on the
Over-the-Counter Bulletin Board. The Company's Form 10, which
contains among other things, recent information about the Company's
business, operations, financial results and capitalization, can be
accessed through the website maintained by the SEC at
http://www.sec.gov.
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is a biotechnology company headquartered
in Philadelphia, PA. The Company
is engaged in the research and clinical and commercial development
of biological products and cancer therapeutics. The Company's AC
Vaccine platform is a therapeutic cancer vaccine.
Forward-Looking Statements
Certain statements in this release are "forward-looking"
statements. Forward-looking statements involve significant risks
and uncertainties, and in light of the significant uncertainties
inherent in such statements, the inclusion of such information
should not be regarded as a representation by the Company that the
objectives and plans of the Company will be achieved. In fact,
actual results could differ materially from those contemplated by
such forward-looking statements. These statements include, but are
not limited to, the Company's immediate need to obtain additional
funding to continue to finance the Company, the Company's plans,
objectives, projections, expectations and intentions such as those
relating to the future development of M-VAX(R) and its other
vaccine candidates, as well as other important factors discussed in
the Company's Form 10. The Company does not undertake any
obligation to release publicly any revisions to these
forward-looking statements or to reflect the occurrence of
unanticipated events.
